# Vertex Announces $10 Billion Takeover Bid for Crinetics and Rare Disease Drug Palsonify

> ma · REPORTED · 2026-07-13

US drugmaker Vertex Pharmaceuticals announced a $10 billion takeover bid for Crinetics Pharmaceuticals, gaining rights to Palsonify, Crinetics' rare endocrine disease drug. The deal was one of the largest biopharma M&A transactions of the year.

About Vertex Pharmaceuticals / Crinetics Pharmaceuticals: Crinetics Pharmaceuticals is a clinical-stage endocrine-focused pharmaceutical company developing novel therapeutics for rare endocrine diseases and endocrine-related tumors.

- Company: Vertex Pharmaceuticals / Crinetics Pharmaceuticals
- Sector: biotech
- Primary source: https://lifesciencedaily.news/biopharma-h1-2026-review-deals-drugs-and-pipeline-shifts/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.